Menu
Search
Home > Courses > Broadly Neutralizing Antibodies for HIV Prevention, Therapy and Cure

Broadly Neutralizing Antibodies for HIV Prevention, Therapy and Cure

Broadly Neutralizing Antibodies for HIV Prevention, Therapy and Cure
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 9/17/2019
Termination Date: 09/16/2022
Review Date: 12/2/2019
Presenter
  • Marina Caskey, MD
    Associate Professor of Clinical Investigation
    The Rockefeller University, New York, NY
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Better understand the challenges to HIV eradication.
  2. Be aware of current immunologic approaches to treat, eradicate or prevent HIV infection.
  3. Know the results of recent clinical trials of HIV immunotherapy and implications for future studies.
Presenter Bio
Marina Caskey, MD
Marina Caskey, MD is an Associate Professor of Clinical Investigation at The Rockefeller University and an attending physician in infectious diseases at New York Presbyterian-Weill Cornell Medical Center. Her research in broadly neutralizing antibodies have revitalized this area of HIV research, which are now considered one of the most promising strategies to achieve HIV remission, as well as potential alternatives to antiretrovirals for both therapy and prevention of HIV disease.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit on September 17, 2019 and will terminate September 16, 2022.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Marina Caskey, MD (Presenter) had no relevant financial relationships to disclose. Dr. Caskey submitted her slides in advance for adequate peer review, and will support her presentation and clinical recommendations with the best available evidence from the medical literature.

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details: 

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules